Le Lézard
Classified in: Health
Subject: RCL

Voluntary Class 1 Recall Announced for Limited Number of PLANTERS® 4 oz. Honey Roasted Peanuts and 8.75 oz. PLANTERS® Deluxe Lightly Salted Mixed Nuts Distributed to Two Retail Locations in Five States


No reports of consumer illnesses and no other PLANTERS® products are involved in this voluntary recall. 

AUSTIN, Minn., May 2, 2024 /PRNewswire/ -- Hormel Foods Sales, LLC is voluntarily recalling two varieties of PLANTERS® products that were produced at one of its facilities in April. This recall only impacts two retailers in five states. These products are being recalled out of an abundance of caution because they have the potential to be contaminated with Listeria monocytogenes, an organism that can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain, and diarrhea. Listeria infection can cause miscarriages and stillbirths among pregnant women. No other PLANTERS® products or retailers are involved in this recall.

There have been no reports of illness related to this recall to date, and all retailers that received the affected product have been properly notified. This recall is being initiated with the knowledge of the US Food and Drug Administration.

The products were only shipped to Publix distribution warehouses in Florida, Georgia, Alabama and North Carolina and to Dollar Tree distribution warehouses in South Carolina and Georgia.

The recalled product is limited to (1) 4 oz. packages of PLANTERS® Honey Roasted Peanuts with a "Best If Used By" date of April 11, 2025 (displayed on package as 04 11 25) and a package UPC code of 2900002097 and (2) 8.75 oz. cans of PLANTERS® Deluxe Lightly Salted Mixed Nuts with a "Best If Used By" date of April 5, 2026 (displayed on the bottom of the can as 05APR26) and a package UPC code of 2900001621 on the side of the can. Photos of the products, "Best If Used By" dates and UPC codes appear below.

No other sizes, varieties, or other packaging configurations of PLANTERS® brand products are included in this recall.

If a consumer has this product, they can discard the product or return it to the store where purchased for an exchange. If consumers have questions, they may contact Hormel Foods Customer Relations via email here, via chat at https://www.planters.com/ or at 1-800-523-4635, Monday-Friday, 8 a.m. ? 11 a.m. and 2 p.m. ? 4 p.m. Central Time, excluding holidays.

Contact:           

Media Relations


Hormel Foods


[email protected]

SOURCE Hormel Foods Corporation


These press releases may also interest you

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...

3 jui 2024
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...

3 jui 2024
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...

3 jui 2024
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...



News published on and distributed by: